Healthcare ETF XLV’s Lull: Why Defensive Stocks Are Quietly Setting Up for a Summer Rotation

While the market obsesses over AI and the S&P 500’s rocket-fueled ascent, the real contrarian trade may be hiding in plain sight. Healthcare, the perennial wallflower of every late-cycle rally, is sitting out the current party. The XLV ETF is frozen at $149.54, matching EWZ’s eerie stillness. Four straight sessions, zero movement, not even a twitch. For most traders, that’s a cue to look elsewhere. For the sharp ones, it’s a signal to start paying attention.

The story here isn’t about what’s happening, but what isn’t. While tech, chips, and AI are the only words anyone wants to hear, defensive sectors like healthcare are being left for dead. The last time this happened, the rotation out of growth and into defensives was sudden, violent, and wildly profitable for those who saw it coming. The market is cyclical, and the pendulum always swings back.

The news cycle is a broken record: AI, IPO mania, and the S&P 500’s historic run. But the real economy is starting to show cracks. Inflation is sticky, the Fed is boxed in, and earnings growth is slowing outside of tech. Healthcare, with its stable cash flows and defensive profile, is quietly building a base. The options market is starting to sniff this out, implied volatility in XLV is creeping higher, and open interest is building in out-of-the-money calls. Someone, somewhere, is betting on a move.

The context is classic late-cycle. When the music stops in growth, defensives get their turn. XLV has underperformed the S&P 500 by -8% YTD, but the sector’s fundamentals are improving. Hospital admissions are up, drug pipelines are robust, and M&A activity is picking up. The ETF’s top holdings, think UnitedHealth, Johnson & Johnson, Pfizer, are trading at multi-year valuation lows relative to the market. The last time this setup occurred was 2018, and XLV outperformed by +10% over the next quarter.

The technicals are quietly bullish. XLV is holding above its 200-day moving average, and the RSI is climbing out of oversold territory. The tape is dead, but the setup is alive. The options market is pricing in a 6% move over the next month, and the skew is to the upside. If you’re looking for a rotation play, this is it.

Strykr Watch

The key level is $149.50, that’s the line in the sand. Support is at $148, resistance at $152. The 50-day moving average is curling higher, and the ETF is coiling for a breakout. If XLV can clear $152, the next stop is $158. The risk is a break below $148, which would invalidate the setup and signal more pain ahead.

The options market is your friend here. Buy calls with a $152 strike, or play the range with a bull call spread. The risk-reward is favorable, and the market is giving you cheap optionality. If the rotation comes, it will be fast and furious.

The risk is that the market stays obsessed with tech and AI, leaving defensives in the dust. But history says that when growth rolls over, healthcare is the first place money goes. The risk is underperformance, not a blowup. Size your position accordingly.

The opportunity is in the rotation. Buy XLV above $150 with a stop at $148. Target $158 over the next quarter. If you’re more aggressive, buy calls or bull call spreads. The payoff is asymmetric, and the risk is defined.

Strykr Take

XLV is the classic late-cycle trade, boring, overlooked, and full of potential. The tape is dead, but the setup is alive. If you’re looking for a rotation play, this is it. Size your risk, buy optionality, and be ready for the move. The market always rotates, and when it does, healthcare will be the first to benefit. Don’t sleep on XLV, this is where the smart money is starting to look.